SEC Tracker
Get the app

Rapport Therapeutics RAPP

Rapport Therapeutics FY 2024: net loss $78.3M; diluted EPS −$3.78

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Rapport Therapeutics reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$78.3MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Diluted EPS−$3.78No year-earlier figure tagged10-K income statement, on EDGAR
  3. Cash and cash equivalents$56.8MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  4. Cash from operations−$64.8MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Rapport Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
  2. Ocugen OCGN public float $279M, Jun 30, 2025
  3. Tonix Pharmaceuticals Holding TNXP public float $271M, Jun 30, 2025
  4. Vanda Pharmaceuticals VNDA public float $269M, Jun 30, 2025
  5. Atea Pharmaceuticals AVIR public float $263M, Jun 30, 2025